# Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

Source: https://onco.cc/trials/nct07555938/  
OnCo record `nct07555938` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Cevostamab in multiple myeloma, now recruiting.

## Summary

Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma is a phase 3 interventional study registered as NCT07555938, led by Hoffmann-La Roche, and recruiting on the registry. Official title: A Phase III, Randomised, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Patients With Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy. Planned enrolment is 380 participants (estimated). The study started in 2026-06-23 and primary completion is expected in 2028-10-31. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: CEVOLUTION
- Tags: ctgov-ingest
- Registry id: NCT07555938
- Phase: 3
- Setting: A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Patients With Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy
- Sponsor: Hoffmann-La Roche
- Enrolled: 380

## Sources

- ClinicalTrials.gov NCT07555938: https://clinicaltrials.gov/study/NCT07555938

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/)
- drugs: [Cevostamab](https://onco.cc/drugs/cevostamab/)
- companies: [Roche / Genentech](https://onco.cc/companies/roche-genentech/)

---
JSON: https://onco.cc/api/v1/entities/nct07555938.json